Update on human campylobacter jejuni infections

Current Opinion in Gastroenterology

Volumn 27, Issue 1, 2011, Pages 1-7

  Kirkpatrick, Beth D ^a   Tribble, David R ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Campylobacter jejuni; Campylobacteriosis; Postinfectious sequelae

Indexed keywords

AZITHROMYCIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN;

ARTICLE; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTERIOSIS; COLONY FORMING UNIT; DIARRHEA; FEVER; GUILLAIN BARRE SYNDROME; HEMATOCHEZIA; IMMUNE RESPONSE; IRRITABLE COLON; MUSCLE CRAMP; SINGLE DRUG DOSE; VACCINE PRODUCTION;

CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; GASTROENTERITIS; HUMANS;

EID: 79951632171     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283413763     Document Type: Article

References (78)

1. Friedman CR, Hoekstra RM, Samuel M, et al. Risk factors for sporadic campylobacter infection in the United States: A case-control study in Food- Net sites. Cli (Pubitemid 38553336)
2. Kapperud G, Skjerve E, Bean NH, et al. Risk factors for sporadic campylobacter infections: Results of a case-control study in southeastern Norway. J Clin Microbiol 1992; 30:3117-3121.
3. Blaser MJ. Epidemiologic and clinical features of campylobacter jejuni infections. J Infect Dis 1997; 176 (Suppl 2):S103-S105. (Pubitemid 27505870)
4. Centers for Disease Control. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food: 10 states 2008. MMWR Morb Mortal Wkly Rep 2009; 59:418-422. Recent incidence estimates of C. jejuni infections within the United States through the Center for Disease Control and Prevention food-borne surveillance system (FoodNet) documenting declining rates since surveillance began in 1996.
5. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human isolates final report, 2007. Atlanta, Georgia: US Department of Health and Human Services, CDC; 2009.
6. Samuel MC, Vugia DJ, Shallow S, et al. Epidemiology of sporadic campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Clin Infect Dis 2004; 38 (Suppl 3):S165-S174. (Pubitemid 38553321)
7. Riddle MS, Sanders JW, Putnam SD, Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): A systematic review. Am J Trop Med Hyg 2006; 74:891-900. (Pubitemid 46774414)
8. Porter CK, Riddle MS, Tribble DR, et al. The epidemiology of travelers' diarrhea in Incirlik, Turkey: A region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagn Microbiol Infect Dis2009; 66:241-247 Clinic-based estimates of traveler's diarrhea and the contribution of C. jejuni among military personnel in Incirlik, Turkey.
9. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: Randomized, double-blind trial comparing single-dose and 3-day azithromycinbased regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338-346. (Pubitemid 46147614)
10. Centers for Disease Control. Surveillance for foodborne disease outbreaks: United States. MMWR Morb Mortal Wkly Rep 2007; 59:973-979.
11. Marshall JK, Thabane M, Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131:445-450; quiz 660. (Pubitemid 44142459)
12. Thabane M, Simunovic M, Akhtar-Danesh N, et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol 2010; 105:933-939. Long-term (8-year) follow-up of children experiencing acute gastroenteritis during the Walkerton, Ontario large C. jejuni and E. coli 0157:H7 waterborne outbreak demonstrating increased risk of postinfectious IBS with similar risk factors as previously observed in adults.
13. Coker AO, Isokpehi RD, Thomas BN, et al. Human campylobacteriosis in developing countries. Emerg Infect Dis 2002; 8:237-244.
14. Taylor DN, Perlman DM, Echeverria PD, et al. campylobacter immunity and quantitative excretion rates in Thai children. J Infect Dis 1993; 168:754-758. (Pubitemid 23254303)
15. Taylor DN, Echeverria P, Pitarangsi C, et al. Influence of strain characteristics and immunity on the epidemiology of campylobacter infections in Thailand. J Clin Microbiol 1988; 26:863-868.
16. Blaser MJ, Taylor DN, Echeverria P. Immune response to campylobacter jejuni in a rural community in Thailand. J Infect Dis 1986; 153:249-254. (Pubitemid 16156056)
17. Ruiz-Palacios GM, Calva JJ, Pickering LK, et al. Protection of breast-fed infants against campylobacter diarrhea by antibodies in human milk. J Pediatr 1990; 116:707-713. (Pubitemid 20162818)
18. Havelaar AH, van Pelt W, Ang CW, et al. Immunity to campylobacter: Its role in risk assessment and epidemiology. Crit Rev Microbiol 2009; 35:1-22. Comprehensive review of the interplay of campylobacter epidemiology and immunity including incidence estimates across the spectrum of C. jejuni exposure leading to asymptomatic infection, ambulatory illness (with or without healthcare utilization), hospitalizations and fatalities within an industrialized country.
19. Baqar S, Rice B, Lee L, et al. campylobacter jejuni enteritis. Clin Infect Dis 2001; 33:901-905. (Pubitemid 32831849)
20. Janssen R, Krogfelt KA, Cawthraw SA, et al. Host-pathogen interactions in campylobacter infections: The host perspective. Clin Microbiol Rev 2008; 21:505-518.
21. Tribble DR, Baqar S, Pang LW, et al. Diagnostic approach to acute diarrheal illness in a military population on training exercises in Thailand, a region of campylobacter hyperendemicity. J Clin Microbiol 2008; 46:1418-1425. (Pubitemid 351563588)
22. Strid MA, Engberg J, Larsen LB, et al. Antibody responses to campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. Clin Diagn Lab Immunol 2001; 8:314-319. (Pubitemid 32217062)
23. Blaser MJ, Sazie E, Williams LP Jr. The influence of immunity on raw milkassociated campylobacter infection. Jama 1987; 257:43-46. (Pubitemid 17205270)
24. Walz SE, Baqar S, Beecham HJ, et al. Preexposure anti-campylobacter jejuni immunoglobulin a levels associated with reduced risk of campylobacter diarrhea in adults traveling to Thailand. Am J Trop Med Hyg 2001; 65:652-656. (Pubitemid 33134610)
25. Black R, Perlman D, Clements M, et al. Human volunteer studies with campylobacter jejuni. In: Nachamkin I, Blaser M, Tompkins L, editors. campylobacter jejuni: Current status and future trends. Washington, DC: American Society for Microbiology; 1992. pp. 9-19.
26. Tribble DR, Baqar S, Scott DA, et al. Assessment of the duration of protection in campylobacter jejuni experimental infection in humans. Infect Immun 2010; 78:1750-1759. This is the first study to demonstrate the duration of protective immunity following an initial infection with C. jejuni. Also, this experimental infection study in humans provides the first direct evidence of cell-mediated immunity as a correlate and/or surrogate for protection from illness upon exposure to C. jejuni.
27. Miller G, Dunn GM, Reid TM, et al. Does age acquired immunity confer selective protection to common serotypes of campylobacter jejuni? BMC Infect Dis 2005; 5:66.
28. Ternhag A, Asikainen T, Giesecke J, Ekdahl K. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with campylobacter species. Clin Infect Dis 2007; 44:696-700.
29. Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in campylobacter species: A registry-based cohort study. J Infect Dis 2005; 191:1050-1055. (Pubitemid 40404362)
30. Nachamkin I. Chronic effects of campylobacter infection. Microbes Infect 2002; 4:399-403. (Pubitemid 34270676)
31. McDowell RM, McElvaine MD. Long-term sequelae to foodborne disease. Rev Sci Tech 1997; 16:337-341.
32. Connor BA. Sequelae of traveler's diarrhea: Focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005; 41 (Suppl 8):S577-S586. (Pubitemid 41691590)
33. HalvorsonHA, SchlettCD, Riddle MS. Postinfectious irritable bowel syndrome: A meta-analysis. Am J Gastroenterol 2006; 101:1894-1899; quiz 942.
34. Gupta A, Nelson JM, Barrett TJ, et al. Antimicrobial resistance among campylobacter strains, United States, 1997-2001. Emerg Infect Dis 2004; 10:1102-1109. (Pubitemid 38697705)
35. Endtz HP, Ruijs GJ, van Klingeren B, et al. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27:199-208.
36. Luangtongkum T, Jeon B, Han J, et al. Antibiotic resistance in campylobacter: Emergence, transmission and persistence. Future Microbiol 2009; 4:189-200. This article provides a current review of the clinically relevant antibiotic resistance, macrolides and fluoroquinolones, in C. jejuni.
37. Segreti J, Gootz TD, Goodman LJ, et al. High-level quinolone resistance in clinical isolates of campylobacter jejuni. J Infect Dis 1992; 165:667-670.
38. Adler Mosca H, Luthy Hottenstein J, Martinetti Lucchini G, et al. Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991; 10:953-957.
39. Streit JM, Jones RN, Toleman MA, et al. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: Report from the SENTRY Antimicrobial Surveillance Program (2003). Int J Antimicrob Agents 2006; 27:367-375.
40. Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in campylobacter jejuni and C. coli: Resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7:24-34. (Pubitemid 32173330)
41. Lindow JC, Poly F, Tribble DR, et al. Caught in the act: In vivo development of macrolide resistance to campylobacter jejuni infection. J Clin Microbiol 2010; 48:3012-3015. This article is the first documented evidence of in-vivo acquired macrolide resistance in a person infected with C. jejuni.
42. Adachi JA, DuPont HL. Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42:541-547; Epub 2006 Jan 17. (Pubitemid 43202528)
43. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006; 74:1060-1066. (Pubitemid 351627416)
44. Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciproflaxacin- resistant campylobacter infection. J Infect Dis 2004; 190:1150-1157. (Pubitemid 39186803)
45. Evans MR, Northey G, Sarvotham TS, et al. Short-term and medium-term clinical outcomes of quinolone-resistant campylobacter infection. Clin Infect Dis 2009; 48:1500-1506.
46. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with campylobacter jejuni. N Engl J Med 2004; 350:239-248. (Pubitemid 38067636)
47. Tam CC, Rodrigues LC, Petersen I, et al. Incidence of Guillain-Barre syndrome among patients with campylobacter infection: A general practice research database study. J Infect Dis 2006; 194:95-97.
48. Allos BM. Association between campylobacter infection and Guillain-Barre syndrome. J Infect Dis 1997; 176 (Suppl 2):S125-S128. (Pubitemid 27505874)
49. Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after campylobacter jejuni enteritis. J Infect Dis 2006; 193:547-555. (Pubitemid 43202746)
50. Godschalk PC, Heikema AP, Gilbert M, et al. The crucial role of campylobacter jejuni genes in antiganglioside antibody induction in Guillain-Barre syndrome. J Clin Invest 2004; 114:1659-1665. (Pubitemid 40385557)
51. Pope JE, Krizova A, Garg AX, et al. campylobacter reactive arthritis: A systematic review. Semin Arthritis Rheum 2007; 37:48-55. (Pubitemid 47087887)
52. Eastmond CJ, Rennie JA, Reid TM. An outbreak of campylobacter enteritis: A rheumatological followup survey. J Rheumatol 1983; 10:107-108. (Pubitemid 13082217)
53. Bremell T, Bjelle A, Svedhem A. Rheumatic symptoms following an outbreak of campylobacter enteritis: A five year follow up. Ann Rheum Dis 1991; 50:934-938.
54. Hannu T, Kauppi M, Tuomala M, et al. Reactive arthritis following an outbreak of campylobacter jejuni infection. J Rheumatol 2004; 31:528-530. (Pubitemid 38337614)
55. Hannu T, Mattila L, Rautelin H, et al. campylobacter-triggered reactive arthritis: A population-based study. Rheumatology (Oxford) 2002; 41: 312-318. (Pubitemid 34537868)
56. DuPont AW. Postinfectious irritable bowel syndrome. Clin Infect Dis 2008; 46:594-599. (Pubitemid 351263502)
57. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
58. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-1101.
59. Haagsma JA, Siersema PD, NJ DEW, Havelaar AH. Disease burden of postinfectious irritable bowel syndrome in The Netherlands. Epidemiol Infect 2010; 12:1-7.
60. Ternhag A, Torner A, Svensson A, et al. Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis 2008; 14:143-148.
61. Kalischuk LD, Buret AG. A role for campylobacter jejuni-induced enteritis in inflammatory bowel disease? Am J Physiol Gastrointest Liver Physiol 2009; 298:G1-G9 This articles reviews evidence and provides proposed pathogenesis for C. jejuniassociated IBD.
62. Ruigómez A, García Rodríguez LA, Pané s J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: Influence of comorbidities. Clin Gastroenterol Hepatol 2007; 5:465-469. (Pubitemid 46575375)
63. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008; 136:1225-1234.
64. Black RE, Levine MM, Clements ML, et al. Experimental campylobacter jejuni infection in humans. J Infect Dis 1988; 157:472-479. (Pubitemid 18071444)
65. Kantele A, Kantele JM, Arvilommi H, Makela PH. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine 1991; 9:428-431.
66. Viret JF, Favre D, Wegmuller B, et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 1999; 67:3680-3685. (Pubitemid 29291550)
67. Pulimood AB, Ramakrishna BS, Rita AB, et al. Early activation of mucosal dendritic cells and macrophages in acute campylobacter colitis and cholera: An in vivo study. J Gastroenterol Hepatol 2008; 23:752-758. (Pubitemid 351519428)
68. Perlman DM, Ampel NM, Schifman RB, et al. Persistent campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV). Ann Intern Med 1988; 108:540-546.
69. Tee W, Mijch A. campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: Comparison of clinical features and review. Clin Infect Dis 1998; 26:91-96. (Pubitemid 28068160)
70. Poly F, Read TD, Chen YH, et al. Characterization of two campylobacter jejuni strains for use in volunteer experimental-infection studies. Infect Immun 2008; 76:5655-5667.
71. Guerry P, Szymanski CM, Prendergast MM, et al. Phase variation of campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect Immun 2002; 70:787-793. (Pubitemid 34083841)
72. Tribble DR, Baqar S, Carmolli MP, et al. campylobacter jejuni strain CG8421: A refined model for the study of campylobacteriosis and evaluation of campylobacter vaccines in human subjects. Clin Infect Dis 2009; 49:1512-1519. This article describes the development of a new C. jejuni experimental infection model which achieves high campylobacteriosis attack rates using a 4log10 inoculum dose reduction from previous experimental models through addition of expanded immunologic screening criteria. This model importantly utilizes a strain with no risk of ganglioside mimicry (and GBS).
73. Baqar S, Tribble DR, Carmolli M, et al. Recrudescent campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well characterized organism. Clin Vaccine Immunol 2010; 17:80-86. This article describes a case of recrudescent infection in an immunocompetent adult following antibiotic treatment. The person was participating in an experimental infection study and was found to not have C. jejuni-specific immune responses despite continued infection with no evidence of immunodeficiency.
74. Scott DA. Vaccines against campylobacter jejuni. J Infect Dis 1997; 176 (Suppl 2):S183-S188. (Pubitemid 27505887)
75. Tribble DR, Baqar S, Scott DA, et al. Clinical development of an inactivated whole cell campylobacter vaccine candidate. Tampere, Finland: Vaccines for Enteric Diseases; 2001.
76. Schrotz-King P, Prokhorova TA, Nielsen PN, et al. campylobacter jejuni proteomics for new travellers' diarrhoea vaccines. Travel Med Infect Dis 2007; 5:106-109. (Pubitemid 46222223)
77. Cohen D, Ashkenazi S, Green MS, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997; 349:155-159. (Pubitemid 27039194)
78. Baqar S, Applebee L, Gilliland T et al. Preclinical murine experiments evaluating a capsule polysaccharide conjugate vaccine against campylobacter jejuni. The 4th International Conference on Vaccines for Enteric Diseases VED 2007. Lisbon, Portugal; 2007.